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A B S T R A C T
Central hypothyroidism (CH) occurs approximately in 1:50,000, and therefore is expected to be one thousand
times rarer compared with primary hypothyroidism. Despite its rarity in the general population, it is much more
common in certain disorders, in which it is frequently associated with other pituitary hormone deﬁciencies. The
aim of this paper is to provide an updated review on the frequency of congenital CH, which is< 1:50,000, and
on its etiology, disregarding CH caused by other genetic defects, such as mutations of transcription factors
involved in pituitary organogenesis or mutations of the genes encoding TRH or TRH receptor.
Introduction
Central hypothyroidism (CH) is biochemically diagnosed by the
coexistence of low circulating free thyroxine (FT4) with low to normal
circulating thyrotropin (TSH), also described as inappropriately low
serum TSH concentrations [1]. Even if within normal limits when ty-
pically measured on blood drawn at daytime, the nocturnal TSH surge
is diminished and the bioactivity of circulating TSH is low in patients
with CH [2].
CH stems from disruption of the hypothalamus-pituitary axis that
leads to insuﬃcient stimulation of thyroid by TSH. TSH production by
the thyrotrophs is induced by TSH-releasing hormone (TRH), a poly-
peptide synthetized from the 29 kDa pre-pro-TRH mainly in the hy-
pothalamic paraventricular nuclei [3]. Thyrotroph cells are localized in
the anteromedial region of the adenohypophysis and account for ap-
proximately 5% of the functional anterior pituitary cells [4]. In com-
parison, the somatotrophs account for approximately 35–50%, making
the thyrotrophs the least common of the hormone-secreting pituitary
cells [4]. This fact has by itself lead to the conclusion that TSH deﬁ-
ciency should be one of the rarest adenohypophyseal hormone in-
suﬃciencies [5]. TSH is a heterodimer glycoprotein consisting of two
subunits, the α-subunit that is identical to the α-subunit of follicle-sti-
mulating hormone (FSH), luteinizing hormone (LH) and human
chorionic gonadotropin (HCG), and the β-subunit that is unique and
confers biologic speciﬁcity. Bioactivity of TSH depends on its glycosy-
lation and is inﬂuenced by the highly-conserved sequence 27CAGYC31
in the β-subunit [5,6].
CH occurs in less than 1 in 50,000 (0.002%) births [7]. Despite its
rarity in the general population, CH is common in patients with certain
disorders. In these patients TSH deﬁciency is frequently associated with
other hormone deﬁciencies (multiple hypopituitarism or panhypopi-
tuitarism). The aim of this paper is to provide an updated review of
such diseases, disregarding CH caused by other genetic defects, such as
mutations of transcription factors involved in pituitary organogenesis
or mutations of the gene encoding TRH or TRH receptor. Epidemiology
and causes of acquired CH are addressed in a companion review.
Methods
A systematic literature search using PubMed and MEDLINE data-
bases was performed using the strings “central hypothyroidism” and
“congenital hypothyroidism”. We excluded all the papers focusing on
primary congenital hypothyroidism and CH resulting either from ge-
netic defects in pituitary organogenesis or from TRH/TRH receptor
mutations.
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Results
As summarized in Tables 1 and 2, in a number of syndromes CH has
a much higher frequency compared to the expected 0.002% (1 in
50,000 births) (see “Introduction”) [7].
Immunogobulin superfamily member 1 (IGSF1) deﬁciency
This X-linked syndrome stands out because of the 100% prevalence
of CH in males and 33% in females. Clinical presentation of this syn-
drome include obesity and macro-orchidism [8]. In a multicentric
European study on 42 patients (24 males) from 10 families, male pa-
tients (age 0–87 years) showed CH in 100% of patients, hypoprolacti-
nemia in 67%, and transient partial growth hormone (GH) deﬁciency in
13%) [8]. Even though testes grew at a normal age and then reached
macro-orchid size, growth spurt, pubic hair development and testos-
terone production through puberty were delayed. Also, three-quarters
of patients over 55 years of age had components of metabolic syn-
drome, and overall, waist circumference, fat percent and body mass
index tended to be elevated [8]. Very recently, a novel IGSF1 mutation
in a 14-year old Japanese boy presenting with CH, short stature and
chronic constipation was reported [9]. It is predicted that the incidence
of IGSF1 deﬁciency-related hypothyroidism is approximately 1:100,000
[10].
Congenital proprotein convertase 1/3 (PC1/3) deﬁciency
Another rare syndrome, inherited in an autosomal recessive mode,
is congenital proprotein convertase 1/3 (PC1/3) deﬁciency [11]. PC1/3
is an endoprotease that processes many prohormones expressed in en-
teroendocrine, endocrine and neuronal cells. Martin et al. evaluated 13
children with PC1/3 deﬁciency [11]. All children were born at term
with normal weights (3.4 ± 0.3 Kg), and all presented with evidence of
dehydration, metabolic acidosis, and malabsorbitive diarrhea during
the ﬁrst two months of life [11]. Children managed to thrive only after
nutritional support. However, as patients aged beyond early infancy,
their weight increased signiﬁcantly. From an endocrine perspective, it
is noteworthy that pituitary deﬁciencies were highly prevalent (dia-
betes insipidus, postprandial hypoglycemia, adrenocorticotropic hor-
mone (ACTH) deﬁciency and TSH deﬁciency in 61% of cases, and GH
and gonadotropin deﬁciencies in less than 50%) (Table 1) [11]. These
endocrine abnormalities are supposed to result from defective proces-
sing of pro-TRH to TRH, proopiomelanocortin to ACTH, and proinsulin
to insulin. Other than GH, PC1/3 processes somatostatin and ghrelin,
which in turn control GH secretion. Species diﬀerences in the cleavage
site sequence of proGHRH may explain why humans are less prone to
GH deﬁciency compared with mice [11]. Also, gonadotropin deﬁciency
may results from altered kisspeptin precursor processing rather than an
altered proGnRH to GnRH conversion. Finally, data assessing the in-
volvement of PC1/3 in processing the human vasopressin is lacking.
Diﬀerent age-dependent expression of PC1/3 and PC2, that is is another
proprotein convertase, may explain development of diabetes insipidus
beyond early infancy [11].
Prader-Willi syndrome (PWS)
PWS is the most common syndromic form of obesity. The prevalence
of PWS in the United States was reported between 1:16,062 and
1:25,000; outside the United States, the reported prevalence has ranged
from 1:8000 in rural Sweden to 1:16,000 in Western Japan [12]. In
regard to the presence of CH in patients with PWS, some studies are
worth mentioning. One Canadian study described the response of TSH
to TRH in children and adolescents (n=21) with PWS, and compared
TSH and total thyroxine (TT4) concentrations measured on neonatal
Table 1
Malformative syndromes associated to central hypothyroidism and relative frequency.
Malformative syndrome Epidemiology Rate of central
hypothyroidism (CH)
Other endocrinological aspects
Immunoglobulin superfamily member 1 (IGSF1)
deﬁciency
1:100,000 100% in males
33% in females
Hypoprolactinemia, GH deﬁciency, delayed pubertal
testosterone production in males, macro-orchidism,
obesity, metabolic syndrome
Congenital proprotein convertase 1/3 (PC1/3)
deﬁciency
? 61% Diabetes insipidus, central adrenal insuﬃciency, GH
deﬁciency, gonadotropin deﬁciency, childhood obesity
Prader-Willi syndrome 1:8000–16000 newborns 5–30% GH deﬁciency, central adrenal deﬁciency, obesity
Septo-optic dysplasia 1:10,000 newborns 45–80% GH deﬁciency, central adrenal insuﬃciency, central
diabetes insipidus, gonadotropin deﬁciency, central
precocious puberty
Arteriohepatic dysplasia (Alagille syndrome) 1:30,000–50,000 newborns ≈30% None
Solitary median maxillary central incisor syndrome 1:50,000 newborns ≈25% Hypopituitarism, short stature, empty sella
Dandy-Walker syndrome 1:10,000–30,000 ? –
Edwards syndrome (Trisomy 18) ≈1:6000 newborns. [5–10% of
them live past their ﬁrst year]
See holoprosencephaly See holoprosencephaly
Holoprosencephaly 1:16,000 11% Central hypocortisolism, GH deﬁciency and diabetes
insipidus
Genoa syndrome ? See holoprosencephaly See holoprosencephaly
Sturge-Weber syndrome 1:20,000–50,000 newborns ≈2.5% GH deﬁciency, central hypogonadism
Rapid-onset Obesity with Hypothalamic
Dysfunction, Hypoventilation, and Autonomic
Dysregulation (ROHHAD) syndrome
≈100 cases reported in the
literature
≈30% Hypothalamic dysfunction, GH deﬁciency, ACTH
deﬁciency, hyperprolactinemia
Table 2
Diseases associated to iron overload-related central hypothyroidism and relative frequency.
Disease Epidemiology Rate of central hypothyroidism
(CH)
Other endocrinological aspects
Sickle cell disease (SCD) 1:500–1400 ≈2% Hyper-/hypogonadotropic hypogonadism, GH deﬁciency, primary hypothyroidism,
osteopenia/osteoporosis, vitamin D deﬁciency
β-thalassemia 1:10,000–100,000 0–35% Hypogonadotropic hypogonadism, diabetes mellitus, impaired glucose tolerance,
hypoparathyroidism, vitamin D insuﬃciency, osteopenia/osteoporosis
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screening for congenital hypothyroidism in children with PWS (n= 23)
and controls [13]. In the ﬁrst group, 1/21 patients (4.8%) had CH
(tertiary hypothyroidism). However, mean FT4 concentration
(10.4 pmol/L; range, 8.2–13.5 pmol/L) was in the lower one-third of
the normal range in 18 of 20 remaining subjects. In these 20 patients,
mean TSH level was 1.9 mU/L (range, 0.8–4.2 mU/L) at baseline and
21.8 mU/L (range, 10.0–46.7 mU/L) at 20min (peak). Serum levels of
TSH and TT4 at birth were not signiﬁcantly diﬀerent between PWS
neonates and controls. The authors concluded that, because of the low
prevalence (1/21) of hypothyroidism, L-T4 treatment should not be
routinely prescribed to youth with PWS [13].
One Dutch study evaluated thyroid function in 75 children with
PWS (median age= 4.7 years) at baseline and one year later during GH
treatment (1mg GH/m2/day; n= 34) or without GH treatment
(n=23, controls) [14]. At baseline, median (interquartile range) TSH,
TT4, FT4 and TT3 levels were −0.1 SDS (−0.5 to 0.5), −0.6 SDS (1.7
to 0.0), −0.8 SDS (−1.3 to −0.3) and 0.3 SDS (−0.3 to 0.9), respec-
tively. Median TT4 and FT4 levels were signiﬁcantly lower than 0 SDS,
while TT3 was signiﬁcantly higher than 0 SDS. In untreated PWS
children thyroid function tests were unchanged. After one year of GH
treatment, FT4 decreased signiﬁcantly from −0.8 SDS (−1.5 to −0.2)
to−1.4 SDS (−1.6 to−0.7), while TT3 was unchanged at 0.3 SDS (0.1
to 0.8). Because T3 levels were relatively high or normal, both before
and during GH treatment, PWS children had increased T4 to T3 con-
version. Peripheral T4 to T3 conversion by deiodinase type 2 might
compensate for the relatively lower FT4. Furthermore, increased leptin
levels and GH treatment may contribute to enhance this conversion
[14].
The aforementioned 5% (1/21) rate of CH in PWS, was challenged
by a recent French paper [15]. Data from 154 patients (68 men), with a
median age of 27 years (range 16–54), revealed that, with a rate of 26%
matching the 25% rate of type 2 diabetes mellitus, hypothyroidism was
one of the most prevalent disorders. Noteworthy, no information on the
level of hypothyroidism (primary, central) was provided [15]. This 26%
rate is consistent with that of a recent review [16]. The review states
that hypothyroidism is reported in approximately 20–30% of children
with PWS and, similar to other endocrinopathies in PWS, the etiology is
thought to be central in origin [16]. By comparison, depending on the
diagnostic criteria used, the reported prevalence of GH or ACTH deﬁ-
ciency in PWS ranged from 40 to 100% or 0 to 60%, respectively [16].
Septo-optic dysplasia (De Morsier syndrome) (SOD)
Septo-optic dysplasia (SOD) is a disorder of early brain development
with an incidence of 1 in 10,000 newborns [17]. Although its signs and
symptoms vary, this condition is traditionally deﬁned by three char-
acteristic features: underdevelopment (hypoplasia) of the optic nerves,
abnormal formation of structures along the midline of the brain, and
pituitary hypoplasia [17].
A retrospective chart review was conducted on a cohort of children
with optic nerve dysplasia or SOD between January 2005 and March
2013 [18]. During the study period, of the 101 patients evaluated
(median age: 2.3 years, range: 0.76–6.5), 73 (72.3%) had hypopitui-
tarism, with GH deﬁciency (62%) and CH (54%) being the most
common abnormalities. Gonadotropin deﬁciency was diagnosed in half
of adolescents evaluated (4/8). Magnetic resonance imaging (MRI) pi-
tuitary abnormalities predicted hypopituitarism with sensitivity and
speciﬁcity of 54% and 92%, respectively. Thus, a normal pituitary
gland did not exclude endocrinopathy [18].
In a retrospective electronic medical record chart review of a ter-
tiary care center’s pediatric endocrinology clinic, 80 patients with SOD
were selected [19]. SOD was diagnosed in patients fulﬁlling at least two
of the following criteria: optic nerve hypoplasia, agenesis/hypoplasia of
septum pellucidum and/or corpus callosum, and hypothalamic-pitui-
tary dysfunction. Hypothalamic-pituitary dysfunction was present in
half (51%) of subjects with optic nerve hypoplasia with (36%) or
without (15%) dysgenesis of septum pellucidum and/or corpus cal-
losum as compared to dysgenesis of septum pellucidum and/or corpus
callosum alone (4%). Overall, 55% of SOD patients had hypothalamic-
pituitary dysfunction, which had been diagnosed within 2 years of age.
CH, GH deﬁciency, central adrenal insuﬃciency and diabetes insipidus
were the most frequent endocrinopathies with a rate of 70%, 55%, 50%
and 30%, respectively [19].
The prevalence of CH in SOD may diﬀer geographically or ethni-
cally, as indicated by the following two studies: one study on 10 Saudi
children with SOD who were observed from October 1999 through to
May 2004 [20], and one on 18 German children who were observed
between 1976 and 1992 [21]. Age of Saudi patients ranged from
18months to 5 years. The mean age of initial presentation for endocrine
evaluation was 14months. The rates of GH deﬁciency, TSH deﬁciency,
ACTH deﬁciency and diabetes mellitus were 100%, 80%, 80%, and
10%, respectively. Finally, two patients (20%) were suspected to have
gonadotropin deﬁciency. At neuroradiological evaluation, 3 patients
had pituitary gland hypoplasia, 2 had pituitary stalk dysplasia with
pituitary stalk either attenuated or not visualized [20]. In the German
study [21], mean age at initial presentation was 1.9 years (range:
1 day–13 years). In contrast to the Saudi study in which only a basal
hormonal evaluation was performed [20], in the German study en-
docrinological investigation consisted of basal and dynamic evaluation
of hypothalamic-pituitary-thyroid, -gonad -adrenal axis, as well as GH-
IGF-1 axis [21]. Particularly, 5 of the 11 patients (45%) tested with
TRH had CH. Two patients (2/9, 22%) had insuﬃcient gonadotropin
response to GnRH. One of the two patients challenged with CRH had
insuﬃcient ACTH response. GH stimulation tests revealed 1 to 7 pa-
tients with GH deﬁciency, based on the test used. Finally, one patient
suﬀered from diabetes insipidus. Overall, multiple pituitary deﬁciency
was present in 7 patients [21]. An empty sella with or without an ec-
topic pituitary was seen in 4 cases [21].
The high frequency of CH in SOD is also demonstrated by a study
from the Indiana University School of Medicine (Indianapolis, USA)
[22]. In this study, medical records of children with CH observed from
1990 to 2006 were reviewed. Forty-two subjects (22 boys) were iden-
tiﬁed, with 57% having SOD, and 98% had multiple pituitary hormone
deﬁciencies, including GH deﬁciency (76%), ACTH deﬁciency (81%)
and central diabetes insipidus (21%) [22].
Arteriohepatic dysplasia (Alagille syndrome) (ALGS)
Approximately 5 times rarer than SOD is ALGS, an autosomal
dominant disorder that most often (94%) results from mutations of the
JAG1 gene (type 1 ALGS). ALGS primarily aﬀects the liver, heart,
skeleton, eye, face, kidney and vasculature. The incidence of ALGS is 1
in 30,000–50,000 live births, but due to the variable phenotype it is
likely to remain underdiagnosed [23]. At least two case reports of CH
can be retrieved in the literature. One article describes panhypopitui-
tarism in a young woman [24], while the other article describes a young
man with GH and TSH deﬁciency [25]. Very recently Italian researchers
wished to verify the involvement of JAG1 variants in the pathogenesis
of congenital thyroid defects and the frequency of unexplained hy-
pothyroidism in a series of ALGS1 patients (n= 21) and 100 unrelated
patients with congenital hypothyroidism (controls) [26]. This research
was complemented by a study of JAG1 variants in vitro and in the
zebraﬁsh. In this article, De Fillipis et al. report a previously unknown
nonautoimmune hypothyroidism in 6/21 (29%) ALGS1 patients, 2 of
them with thyroid hypoplasia. Two JAG1 variants in the heterozygous
state were found in 4% of controls (4/100) [26]. The role of JAG1 gene
in the pathogenesis of congenital hypothyroidism was demonstrated in
zebraﬁsh, in which a primary thyroid defect resulted from knocking
down jag1a/b (orthologous of the human JAG1) expression [26].
S. Benvenga et al. Journal of Clinical & Translational Endocrinology 14 (2018) 5–11
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Solitary median maxillary central incisor syndrome (SMMCIS)
SMMCIS is as rare as ALGS, as it occurs in 1:50,000 live births [27].
SMMCIS includes severe to mild intellectual disability, holoprosence-
phaly, congenital heart disease, and midline defects such as congenital
nasal malformation, solitary median maxillary central incisor, cleft lip
and/or palate, abnormal pituitary morphology, hypopituitarism, hy-
pothyroidism and short stature [27,28].
Dandy-Walker Syndrome (DWS)
DWS is a congenital brain malformation involving the cerebellum
and the ﬂuid ﬁlled spaces around it, occurring in 1 in 10,000–30,000
newborns [29]. There are three main DWS features: i) partial or com-
plete absence of the cerebellar vermis; ii) enlargement of the fourth
ventricle with or without increased intracranial pressure; iii) cyst for-
mation near the base of the skull. Absence of the corpus callosum and
noncerebral malformations (heart, face, limbs) may occur. Clinical
presentation ranges from progressive enlargement of the skull and
symptoms of intracranial hypertension to slow motor development
[29]. Ten to 20% percent of patients are diagnosed in late childhood or
in adulthood because of headaches, facial palsy, muscular hypertonicity
and unsteady walking gait. DWS is associated with trisomy of chro-
mosome 13, 18 (see below), and 21 [30]. There is at least one report of
CH in DWS, a 3-month-old Saudi boy [31].
Trisomy 18 (Edwards syndrome), holoprosencephaly and Genoa syndrome
Edwards syndrome is the second most common trisomy after Down
syndrome, as it occurs in approximately 1 in 5000 live-born infants.
Although most cases result in termination or fetal loss, live births have
been documented in 5%. Five to 10 percent of children with trisomy 18
live past their ﬁrst year [32]. A few patients (especially girls) can live
into their twenties or thirties although they need full time caregiving.
Edwards syndrome is characterized by multisystem anomalies, in-
cluding microcephaly, micrognathia, malformed ears, microphthalmia,
short sternum, syndactyly, accessory ﬁngers, cardiac, and renal ab-
normalities. Cranial malformations include holoprosencephaly, absence
of the corpus callosum and spina biﬁda [33]. CH, central adrenal in-
suﬃciency, GH deﬁciency and central diabetes insipidus have been also
reported. These endocrinopathies are common in patients with holo-
prosencephaly, which is the most common developmental defect of the
forebrain and mid-face, occurring in 1:16,000 live births [33,34]. Facial
anomalies include cyclopia, ocular hypotelorism, proboscis, cleft lip/
palate and median maxillary central incisor [34].
Holoprosencephaly (MIM 236100) results from incomplete cleavage
of the prosencephalon at 18th–28th day of gestation, and it is associated
to abnormal development of the hypothalamus and the pituitary gland
[34]. In 30% of cases at least one of the following genes is mutated:
SHH, ZIC2, SIX3, TGIF, PTCH, GLI2 and TDGF1. According to the se-
verity, holoprosencephaly can be divided into three forms: lobar ho-
loprosencephaly (right and left ventricles are separated, but with some
continuity across the frontal cortex), semilobar holoprosencephaly
(right and left ventricle are partially separated), and alobar holopro-
sencephaly (single median ventricle and no interhemispeheric ﬁssure).
In a cohort of 117 such patients, the rate of diabetes insipidus, CH,
central adrenal insuﬃciency, and GH deﬁciency, was 70%, 11%, 7%,
and 5%, respectively [35]. Indeed, in a postportem study on trisomy 18
fetuses, the authors have demonstrated a malformation in the sella
turcica/pituitary gland complex in all the fetuses, suggesting a cytos-
keleton alteration of the surface ectoderm in the pituitary placode [36].
Another rare syndrome characterized by holoprosencephaly is
Genoa syndrome, which was ﬁrst described after the name of the Italian
city where the two patients were described in 1993 [37]. The two pa-
tients had semilobar holoprosencephaly, craniosynostosis involving the
coronal and lambdoid sutures and abnormal small hands with cone-
shaped epiphyses and hypoplastic terminal phalanges of ﬁngers. Ge-
netics of Genoa syndrome is still unknown [37].
Encephalotrigeminal angiomatosis (Sturge-Weber syndrome) (SWS)
SWS is a congenital, non-familial disorder of unknown incidence
and cause. A somatic c.548G > A mutation in GNAQ [encoding gua-
nine nucleotide–binding protein, q polypeptide (MIM600998)] was
indeed identiﬁed in 88% and 92% of patients with SWS and non–-
syndromic port–wine stains, respectively [38]. SWS is a neurocutaneous
disorder characterized by port-wine birthmark in the distribution of the
ophthalmic branch of the trigeminal nerve, and venous-capillary ab-
normalities of the leptomeninges and the eye. Stasis results in ischemia
and necrosis. Neurological manifestations are variable, including sei-
zures, stroke and mental retardation. Glaucoma is also common
[38–40].
The incidence of SWS is estimated at 1 person per 20,000–50,000
[41]. Comi et al. [42] described two children out of 83 (2.4%) with SWS
and CH. The authors concluded that, because the 2.4% prevalence of
CH is much greater than in the general population, thyroid function
testing is important in SWS patients despite no symptoms of hy-
pothyroidism [42]. Another two cases of SWS with low FT4 and pre-
sumable CH were reported elsewhere [43]. Very recently, CH was re-
ported in a 11-yr old boy with SWS [44]. He was familiarly predisposed
to hypothyroidism in both his maternal and paternal grandmother. The
patient had a positive history for convulsions, but did not take any
anticonvulsants. Thyroid function tests were performed, and were
consistent with CH. Indeed, FT4 was 0.62 ng/dl (normal range,
0.7–1.6 ng/dl), TT4 was 4.5 μg/dl (normal range 5.5–11.0 μg/dl) and
TSH 2.69 IU/ml (normal range, 0.47–4.68 IU/ml) [44]. Finally, GH
deﬁciency and hypogonadotropic hypogonadism have been also re-
ported in SWS patients [45,46].
Rapid-onset obesity with hypoventilation, hypothalamic dysfunction and
autonomic dysregulation (ROHHAD)
ROHHAD is a rare syndrome that aﬀects the autonomic nervous
system (such as inability to regulate body temperature, slow heartbeat,
excessive sweating, altered pupil response to light, strabismus, and/or
intestinal abnormalities), hyper- or hyponatremia, and the endocrine
system [47]. As cited by Kocaay et al. [48], at the time of their case
reports there were only 78 patients described in the literature. An ar-
ticle published one year later, stated “fewer than 100 case reported in
the literature” [49].
As the name suggests, the most characteristic features include dra-
matic weight gain over a six- to 12-month period in the ﬁrst 10 years of
life followed by hypothalamic dysfunction, dysregulation of the auto-
nomic nervous system, and alveolar hypoventilation. The exact un-
derlying cause of ROHHAD, including a precise genetic basis, is cur-
rently unknown [49]. The endocrine disorders include TSH deﬁciency,
GH deﬁciency, ACTH deﬁciency, hyperprolactinemia, early or late
puberty. The long-term prognosis for people with ROHHAD varies.
ROHHAD children are at increased risk for certain types of tumors in-
cluding ganglioneuromas and ganglioneuroblastomas, and sudden
death for cardiac arrest occurs due to alveolar hypoventilation [47].
Due to the occurrence of ganglioneuromas (located in the abdomen and
lungs) and neuroendocrine tumors, such as ganglioneuroblastoma, in
about 40% of the patients, the disease is now also called ROHHAD-
neuroendocrine tumors (ROHHADNET). ROHHAD may fail to be di-
agnosed early [48]. In a 13-year-old female patient who was reported to
be healthy until the age of 3 years, CH, hyperprolactinemia, Raynaud
phenomenon and electrolyte disorders were all ﬁndings that had been
identiﬁed three years before the patient’s presentation to the authors’
clinic, but these ﬁndings were not interpreted together to reach a di-
agnosis. The authors underscore that the possibility of ROHHAD syn-
drome needs to be considered in all pediatric cases of early- and rapid-
S. Benvenga et al. Journal of Clinical & Translational Endocrinology 14 (2018) 5–11
8
onset obesity associated with hypothalamic-pituitary endocrine dys-
function [48], a message that is echoed in another case report [50]. This
second article describes two girls who presented with rapid weight
gain, at the age of 5 and 9 years respectively. The ﬁrst was admitted due
to obesity and CH. After two months she developed autonomic nervous
system dysregulation (thermal dysregulation), alveolar hypoventila-
tion, hypodipsia, severe hypernatriemia, and hypertriglyceridemia. The
second case was admitted three months after diagnosis of mild hyper-
prolactinemia associated with rapid-onset obesity, due to seizures, hy-
pothermia, and electrolyte disorders (hyponatriemia followed by severe
hypernatriemia). CH and ACTH deﬁciency were also diagnosed [50]. In
another case report, the ﬁrst in Southeast Asia, CH was diagnosed at age
5 while ACTH deﬁciency at age 11 [51]. The authors also reviewed the
52 ROHHAD cases previously reported in literature, in whom CH and
GH deﬁciency were diagnosed in≈ 30% and≈ 50%, respectively [51].
Sickle cell anemia (SCD)
SCD is an autosomal recessive inherited hemolytic anemia. SCD is
the most common inherited blood disorder in the United States. Indeed,
SCD is most common in Mediterranean people, Arabians, Indians, and
in all the people descending from African ancestors [52]. Endocrine
complications of SCD result from either iron overload or ischemia due
to vaso-occlusive crisis occurring within endocrine glands [53].
In one paper, 50 Turkish children and adolescents with SCD were
evaluated for endocrine problems [53]. Mean age of patients was
13.1 ± 2.9 years, and 50% of patients had at least one endocrine ab-
normality. Hypergonadotropic hypogonadism was detected in 3 pa-
tients (6%), hypogonadotropic hypogonadism in 1 female patient (2%),
and small testicular volume in respect to age in 3 male patients (8.5%).
GH deﬁciency was detected in 1 (2%) female patient, while CH and
primary hypothyroidism in 1 (2%) and 2 cases (4%), respectively [53].
American authors reported the occurrence of hypothyroidism in three
adult patients (> 45 years of age at time of diagnosis) with SCD [54].
All three patients had received multiple units of transfused red blood
cells and had serum ferritin levels of greater than 6000 ng/mL. All
patients were critically ill at the time of the diagnosis of hypothyr-
oidism and died shortly after for congestive heart failure. Postmortem
examination in one patient revealed ﬁbrosis of the thyroid together
with iron deposition [54].
β-thalassemia
Thalassemia is the most common hereditary anemia, which is
transmitted in an autosomal recessive manner, and β-thalassemia major
is its most severe form. Thousands of infants with β-thalassemia are
born each year [55]. Approximately 1.5% of the global population are
carriers of β-thalassemia, with an annual incidence of 1 in 100,000
across the world and 1 in 10,000 in Europe. Cyprus, Sardinia and
Southeast Asia are the regions with the highest frequency of β-tha-
lassemia carriers. According to Thalassemia International Federation,
approximately 200,000 patients with β-thalassemia major are alive
[56]. Iron overload-related complications, including the endocrine
ones, depend on the use of iron chelation, since patients who are reg-
ularly treated with iron chelation therapy have less severe complica-
tions and live beyond their 40 s [56].
A multicentric study from USA, Canada and United Kingdom com-
pared iron-overloaded subjects with thalassemia (group I, n= 142, age
25.8 ± 8.1 years) and transfused SCD (group II, n= 199,
24.9 ± 13.2 years) to non-transfused SCD subjects (group III, n= 64,
25.3 ± 11.3 years) [57]. In group I, diabetes, hypogonadism, hy-
pothyroidism and growth failure were more frequent compared to
group II (13% vs. 2%, P < 0.001; 40% vs. 4%, P < 0.001; 10% vs. 2%,
P < 0.001; 33% vs. 7%, P < 0.001, respectively) [57]. It is note-
worthy to say that hypothyroidism was deﬁned as ongoing thyroid
hormone replacement therapy, thus irrespective of the etiology.
Overall, the rate of multiple endocrinopathy (≥2) was four or seven
times greater in group I than group II or group III (56% vs. 13% or 8%,
P < 0.001). At multivariate analysis, group I patients had 9.4 times
higher odds of overall endocrinopathy, with the duration of chronic
transfusion being a predictor of endocrine failure. In contrast, iron
overload did not increase the risk of endocrinopathy in group II, sug-
gesting a role of the underlying disease in the pathogenesis of the en-
docrine injury [57].
De Sanctis et al. performed a cross-sectional analysis on 339 β-
thalassemia major patients. All patients were on chelation therapy from
the prepubertal or peripubertal age. Twenty-six out of 339 (7.6%) were
diagnosed with CH [58]. Particularly, the rate of CH in pre-pubertal age
(< 11 years), peri-pubertal age (11–16 years) and pubertal age
(> 16 years) was 0%, 22% and 7.8%, respectively. Furthermore, 12/26
(46.1%) CH patients had an associated hypogonadotropic hypogo-
nadism, 4/26 (15.3%) short stature, 2/26 (7.7%) insulin-dependent
diabetes mellitus, and 1/26 (3.8%) hypoparathyroidism [58]. Even
though serum ferritin did not diﬀer signiﬁcantly between hypothyroid
and euthyroid patients, the authors did not exclude the role of iron
overload in the pathogenesis of CH. In addition, normal ferritin may not
rule out iron overload in some tissue [58]. Concomitant hepatitis C
infection, which was present in three-quarters of patients, increased
collagen deposition secondary to increased activity of the iron-depen-
dent protocollagen proline hydroxylase enzyme, and the hypoxic eﬀect
of chronic anemia have been proposed also for the hypothalamic-pi-
tuitary dysfunction [58].
A study from Qatar investigated thyroid function in 48 patients with
thalassemia major between 5 and 18 years of age [59]. Over a 12-year
follow-up hypothyroidism was diagnosed in 35% (17/48) of patients,
who all except one were>10 years old. Thirteen out of 17 patients
(13/48, 27%) had CH. FT4, but not TSH, correlated negatively with age
(r=−0.595, P < 0.0001) suggesting a progressive hypothalamic-pi-
tuitary dysfunction over time [59]. In an Iranian cross-sectional study
on 77 patients with β-thalassemia major (mean age
21.26 ± 4.53 years; range 15–36) rates of impaired puberty, short
stature, hypothyroidism, diabetes mellitus, impaired glucose tolerance,
hypoparathyroidism, vitamin D deﬁciency and vitamin D insuﬃciency
were 46.8%, 33.8%, 18.2%, 16.9%, 13.0%, 7.8%, 45.5% and 24.7%,
respectively [60]. No details are given in regard to the level of hy-
pothyroidism (primary, secondary), since all patients with reduced FT4
or increased TSH or on levothyroxine were included [60].
In a multicenter study from Cyprus on 435 thalassemic patients, the
most prevalent endocrine complications were short stature (35%) and
hypogonadotropic hypogonadism (32.5%), followed by hypothyroidism
(5.9%), hypoparathyroidism (1.2%) and diabetes mellitus (9.4%). Type
of hypothyroidism (primary or central) was not speciﬁed, although the
authors clarify that primary thyroid dysfunction occurs in most cases
before hypothalamic-pituitary disruption by hemosiderosis [61]. Thus,
CH is much less common compared to primary hypothyroidism [61,62].
This observation was conﬁrmed by a Greek study on 200 β-thalassemia
patients regularly transfused and desferioxamine chelated [63]. In this
study, all the 33 patients (16.5%) with thyroid dysfunction had either
overt primary hypothyroidism (i.e. increased TSH levels, low FT4 and/
or FT3; n=8, 4%) or subclinical primary hypothyroidism (increased
basal TSH levels, normal FT4 and FT3, exaggerated TSH response after
TRH infusion; n= 25, 12.5%). No case of CH was observed [63]. Pri-
mary thyroid hypofunction usually appears in the second decade of life
and may be reversible upon intensive and precocious chelation [61,62].
In a multicentric Italian study on a large cohort of β-thalassemia pa-
tients, primary hypothyroidism occurred as frequently (6.2%) as in the
Cypriot study mentioned above, although earlier (mean age 15.8 years)
[64].
Discussion
The prevalence of hypothyroidism in the general population ranges
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from 0.3% to 3.7% in the United Stated, and from 0.2% to 5.3% in
Europe, with an average overall prevalence of 2–3%. CH is a rare cause
of thyroid hormone deﬁciency, since it is expected to occur around one
thousand times less frequently compared to primary hypothyroidism
[65].
In this review we have shown that, despite its rarity in the general
population, CH is much common in certain disorders. These disorders
can be divided into either malformative syndromes characterized by an
altered hypothalamus-pituitary development or diseases in which pi-
tuitary impairment results from iron overload (SCD and β-thalassemia).
In patients with such disorders CH has a variable prevalence, ranging
from 2% to 100%, and is frequently associated with other pituitary
hormone deﬁciencies (see Tables 1 and 2). Concerning SCD and β-
thalassemia, thyroid hemosiderosis occurs generally before hypotha-
lamus-pituitary hemosiderosis, resulting in a greater rate of primary
hypothyroidism compared with CH [61].
In conclusion, all the patients with the disorders mentioned above
should be screened for CH. Indeed, thyroid function testing should not
be limited to TSH, since it can be normal, but should include also FT4
[66].
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